期刊文献+

基于常规实验室检查指标的改良WPSS预后积分系统对骨髓增生异常综合征预后判断意义的初步研究 被引量:9

The prognostic value of a modified WPSS based on routine laboratory parameters in patients with myelodysplastic syndromes: a preliminary result
原文传递
导出
摘要 目的评价WPSS预后积分系统在我国骨髓增生异常综合征(MDS)患者预后判断中的作用,并对常规实验室检查指标用于MDS患者预后判断进行初步研究。方法对染色体核型结果可供分析的164例成人原发MDS患者进行回顾性分析。结果164例患者中位随访时间19(1—138)个月,中位生存(MS)期36个月,2年预期生存(PS)率60%,5年PS率42%。按WPSS评分,极低危组、低危组、中危组、高危组和极高危组的2年PS率分别为100%、96%、81%、38%和14%,5年PS率分别为100%、83%、54%、20%和0,Log—rank检验各组总体生存(OS)率差异有统计学意义(P〈0.01)。常规实验室检查中,Hb≥80g/L、平均红细胞体积(MCV)升高(〉95fl)、平均红细胞血红蛋白含量(MCH)升高(〉32pg)、BPC≥100×10^9/L的患者预后较好;骨髓原始细胞比例(Blast)≥0.05的患者较〈0.05的患者预后差,骨髓细胞发育异常≥2系的患者预后较差;细胞组化检查中性粒细胞碱性磷酸酶(N-ALP)阳性指数升高(〉173.21)、有核红细胞糖原染色(E—PAS)阴性的患者预后较好,小巨核酶标染色可见淋巴样小巨核细胞(MEGly)的患者预后较差。另外,血清乳酸脱氢酶水平升高(≥300U/L)的患者预后较差。将上述单因素分析有预后意义的参数纳入COX多因素模型筛选,MCV、MEGly、Blast具有独立预后意义(P值分别为0.011、0.013、0.016)。选取MCV、MEGly及WHO分型提出改良的WPSS积分系统,低危组、中危组、高危组患者的2年PS率分别为94%、68%和49%,5年PS率分别为86%、53%和14%,经Log—rank检验各组OS率差异有统计学意义(P〈0.01)。结论与WHO分型相适应的WPSS适合用于判断我国MDS患者的预后。采用常规实验室检查指标中的MCV、MEGly及WHO分型提出的改良WPSS积分系统可望提供适于我国现阶段基层单位的MDS预后判断标准。 Objective To investigate the prognostic value of a modified WPSS based on routine laboratory parameters in Chinese patients with myelodysplastic syndromes (MDS). Methods One hundred and sixty four adult MDS patients were retrospectively analyzed. Results The median follow-up time was 19 ( 1 - 138 ) months and the median survival(MS) was 36 months. 2-year prospective survival(PS) was 60% and 5- year PS was 42%. In patients with very low-risk, low-risk, intermediate-risk, high-risk and very high-risk stratified by WPSS, 2-year PS was 100% , 96% , 81% , 38% and 14% , and 5-year PS was 100% , 83% , 54%, 20% and 0, respectively ( P 〈 0.01 ). Among parameters of laboratory routine examination, elevated mean cell volume (MCV) , mean cell hemoglobin (MCH) , neutrophil alkaline phosphatase (N-ALP) index and nucleated RBC PAS negative were good prognostic factors, while reduced Hb, BPC and bone marrow elevated blasts, dysplasia more than 1 lineage, and lymphocyte-like micromegakaryocyte ( MEGly ) as well aselevated serum LDH were poor prognostic factors in uni-variable analysis. Among them, MCV, MEGly and blast had independent prognostic significance in multi-variable analysis (P = 0. 011, 0. 013 and 0. 016, respectively). WPSS was modified by omitting chromosomal karyotype and ,transfusion dependence and adding MCV and MEGly. In patients with low-risk, intermediate-risk and high-risk stratified by modified WPSS, 2- year PS was 94% , 68% and 49% , respectively; and 5-year PS was 86% , 53% and 14% , respectively ( P 〈 0.01 ). Conclusion The modified WPSS worked well for prognostic prediction in Chinese patients with MDS.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第5期313-317,共5页 Chinese Journal of Hematology
基金 国家自然科学基金(30670899) 天津市自然科学基金重点项目(08JCZDJC19200) 高等学校博士学科点专项科研基金(20050023033) 国家科技支撑计划(2008BA161B02)
关键词 骨髓增生异常综合征 预后 WHO分型预后积分系统(WPSS) Myelodysplastic syndromes Prognosis WHO classification-based prognostic scoring system (WPSS)
  • 相关文献

参考文献10

  • 1Malcovati L, Germing U, Kuendgen A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood, 2005,106: 788.
  • 2Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002,100:2292-2302.
  • 3肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9
  • 4宋玉华.血细胞的组织化学//邓家栋,杨崇礼,杨天楹,等.邓家栋临床血液学.上海:上海科学技术出版社,2001:132-148.
  • 5Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997,89:2079-2088.
  • 6Wimazal F, Sperr WR, Kundi M, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res, 2001, 25:287-294.
  • 7于明华,刘世和,邵英起,郝玉书,肖志坚.原发性骨髓增生异常综合征患者染色体核型与IPSS危度分组:FAB与WHO分型比较[J].中华血液学杂志,2004,25(8):482-485. 被引量:12
  • 8Bemasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with eytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol, 2007,137 : 193-205.
  • 9Tennant GB, Al-Sabah AI, Burnett AK. Prognosis of myelodysplasic patients : non-parametric muhiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol, 2002, 119 : 87-96.
  • 10Oguma S, Yoshida Y, Okuma M, et al. Mode of disease progression in primary myelodysplastic syndromes: a Japanese co-operative study. The Refractory Anemia Study Group of The Ministry of Health and Welfare, Japan. Leuk Res, 1997,21:241-247.

二级参考文献29

  • 1肖志坚,郝玉书.儿童骨髓增生异常综合征的诊断分型[J].中华儿科杂志,2005,43(7):545-547. 被引量:7
  • 2肖志坚.重视和加强我国儿童骨髓增生异常综合征的研究[J].中国小儿血液,2005,10(3):97-98. 被引量:6
  • 3肖志坚.骨髓增生异常综合征:现况与问题[J].白血病.淋巴瘤,2005,14(4):193-196. 被引量:31
  • 4Harris NL, Jaffe ES, Diebold T,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol,1999,17:
  • 5Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol,2000,72:131-133.
  • 6Vardiman JW,Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms.Blood, 2002,100: 2292-2302.
  • 7Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood, 1997,89: 2079-2088.
  • 8Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res, 2000,24:983-992.
  • 9Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood, 2001, 98:2935-2941.
  • 10Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood,2002, 100(7) :2292-2302.

共引文献19

同被引文献86

  • 1褚金龙,刘艳春,李骏,果丽实,刘洪涛,李伟,柴铁.骨髓增生异常综合征患者血清铁蛋白、叶酸与维生素B_(12)检测及其临床意义[J].中国综合临床,2005,21(9):802-803. 被引量:25
  • 2田胜利,周永明,周韶虹,胡明辉,陆嘉惠,罗梅宏,许毅,袁乃荣,魏学礼.骨髓增生异常综合征患者β_2-微球蛋白及血清铁蛋白和C反应蛋白检测的临床意义[J].临床血液学杂志,2006,19(3):142-143. 被引量:8
  • 3曹志红,祝焱,彭敏源.急性白血病LDH及HBDH测定的临床意义[J].实用预防医学,2007,14(2):489-490. 被引量:10
  • 4Turgeon ML.Clinical hematology:theory and procedures.4th ed.Philadelphia:Lippincott Williams & Wilkins,2005.
  • 5Swerdlow SH,Campo E,Harris NL,et al.WHO classification of tumours of haematopoietic and lymphoid tissues.4th ed.IARC:Lyon,2008.
  • 6Valent P,Horny HP,Bennett JM,et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes:Consensus statements and report from a working conference.Leuk Res,2007,31:727-736.
  • 7王良绪 杨慎 莫庆义.血细胞过碘酸-雪夫氏反应对几种血液病诊断价值的探讨[J].天津医药杂志输血及血液学附刊,1964,.
  • 8王友赤 金泰运 谢丽英等.各种贫血的骨髓中幼稚红细胞过碘酸-雪夫氏反应的观察[J].天津医药杂志输血及血液学附刊,1964,.
  • 9Hasserjian RP,Zuo Z,Garcia C,et al.Acute erythroid leukemia:a reassessment using criteria refined in the 2008 WHO classification.Blood,2010,115:1985-1992.
  • 10Wang H,Wang X,Xu X,et al.Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes.Ann Hematol,2010,89:671-679.

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部